Published in Brain on July 11, 2008
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2011) 4.25
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging (2010) 2.05
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage (2009) 1.71
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69
Surgery and brain atrophy in cognitively normal elderly subjects and subjects diagnosed with mild cognitive impairment. Anesthesiology (2012) 1.67
Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls. Neuroimage (2009) 1.63
Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry. Hum Brain Mapp (2010) 1.55
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp (2011) 1.53
Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. Eur Radiol (2009) 1.43
Hippocampal atrophy and ventricular enlargement in normal aging, mild cognitive impairment (MCI), and Alzheimer Disease. Alzheimer Dis Assoc Disord (2012) 1.40
Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans. Neurobiol Aging (2010) 1.30
Power calculations for clinical trials in Alzheimer's disease. J Alzheimers Dis (2011) 1.30
Investigating structural brain changes of dehydration using voxel-based morphometry. PLoS One (2012) 1.22
Hierarchical anatomical brain networks for MCI prediction: revisiting volumetric measures. PLoS One (2011) 1.09
Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline. Neurobiol Aging (2010) 1.09
Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease. J Alzheimers Dis (2010) 1.07
Retinal microvascular signs and 10-year risk of cerebral atrophy: the Atherosclerosis Risk in Communities (ARIC) study. Stroke (2010) 1.03
Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features. Neuroimage (2013) 1.03
Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer's disease. Brain Imaging Behav (2012) 0.92
Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer's disease. BMC Neurol (2013) 0.92
Genetic determinants of disease progression in Alzheimer's disease. J Alzheimers Dis (2015) 0.92
Brain structure and aging in chronic temporal lobe epilepsy. Epilepsia (2012) 0.91
Alzheimer's disease: rapid and slow progression. J R Soc Interface (2011) 0.90
Diffeomorphic brain mapping based on T1-weighted images: improvement of registration accuracy by multichannel mapping. J Magn Reson Imaging (2012) 0.90
Multilocus genetic profiling to empower drug trials and predict brain atrophy. Neuroimage Clin (2013) 0.89
Ventricular enlargement in new-onset pediatric epilepsies. Epilepsia (2011) 0.88
MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. Front Aging Neurosci (2014) 0.87
Mapping ventricular expansion onto cortical gray matter in older adults. Neurobiol Aging (2014) 0.87
Heritability of brain ventricle volume: converging evidence from inconsistent results. Neurobiol Aging (2010) 0.87
Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimers Res Ther (2014) 0.85
Morphometric changes in lateral ventricles of patients with recent-onset type 2 diabetes mellitus. PLoS One (2013) 0.85
High degree of heterogeneity in Alzheimer's disease progression patterns. PLoS Comput Biol (2011) 0.85
Lesion Explorer: a video-guided, standardized protocol for accurate and reliable MRI-derived volumetrics in Alzheimer's disease and normal elderly. J Vis Exp (2014) 0.84
White matter abnormalities and structural hippocampal disconnections in amnestic mild cognitive impairment and Alzheimer's disease. PLoS One (2013) 0.84
Cholesterol increases ventricular volume in a rabbit model of Alzheimer's disease. J Alzheimers Dis (2012) 0.83
A pilot study of quantitative MRI measurements of ventricular volume and cortical atrophy for the differential diagnosis of normal pressure hydrocephalus. Neurol Res Int (2011) 0.83
ApoE ε4 Is Associated With Cognition, Brain Integrity, and Atrophy in HIV Over Age 60. J Acquir Immune Defic Syndr (2016) 0.83
Detecting Anatomical Landmarks for Fast Alzheimer's Disease Diagnosis. IEEE Trans Med Imaging (2016) 0.82
Adolescent Development of Cortical and White Matter Structure in the NCANDA Sample: Role of Sex, Ethnicity, Puberty, and Alcohol Drinking. Cereb Cortex (2015) 0.82
Dietary cholesterol increases ventricular volume and narrows cerebrovascular diameter in a rabbit model of Alzheimer's disease. Neuroscience (2013) 0.82
Multimodality imaging of Alzheimer disease and other neurodegenerative dementias. J Nucl Med (2014) 0.82
Cognitive function and brain structure after recurrent mild traumatic brain injuries in young-to-middle-aged adults. Front Hum Neurosci (2015) 0.82
Subcortical hyperintensity volumetrics in Alzheimer's disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory. Alzheimers Res Ther (2014) 0.81
Slow gait in MCI is associated with ventricular enlargement: results from the Gait and Brain Study. J Neural Transm (Vienna) (2012) 0.81
The diffeomorphometry of regional shape change rates and its relevance to cognitive deterioration in mild cognitive impairment and Alzheimer's disease. Hum Brain Mapp (2015) 0.81
Cholesterol and copper affect learning and memory in the rabbit. Int J Alzheimers Dis (2013) 0.81
Mapping Dynamic Changes in Ventricular Volume onto Baseline Cortical Surfaces in Normal Aging, MCI, and Alzheimer's Disease. Multimodal Brain Image Anal (2013) (2013) 0.81
Depressive symptoms in prodromal Huntington's Disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex. Psychiatry Res (2012) 0.81
Genetic modification of the relationship between phosphorylated tau and neurodegeneration. Alzheimers Dement (2014) 0.81
Estimation of the lateral ventricles volumes from a 2D image and its relationship with cerebrospinal fluid flow. Biomed Res Int (2013) 0.80
Significance of normalization on anatomical MRI measures in predicting Alzheimer's disease. ScientificWorldJournal (2014) 0.79
Predicting Alzheimer's disease development: a comparison of cognitive criteria and associated neuroimaging biomarkers. Alzheimers Res Ther (2015) 0.79
Dynamic Progression of White Matter Hyperintensities in Alzheimer's Disease and Normal Aging: Results from the Sunnybrook Dementia Study. Front Aging Neurosci (2016) 0.79
Biomarkers for Alzheimer's disease: ready for the next step. Brain (2009) 0.78
Callosal microstructural abnormalities in Alzheimer's disease and alcoholism: same phenotype, different mechanisms. Psychiatry Res (2010) 0.78
Multivariate longitudinal shape analysis of human lateral ventricles during the first twenty-four months of life. PLoS One (2014) 0.78
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
Vascular pathology of 20-month-old hypercholesterolemia mice in comparison to triple-transgenic and APPSwDI Alzheimer's disease mouse models. Mol Cell Neurosci (2014) 0.77
Classification and localization of early-stage Alzheimer's disease in magnetic resonance images using a patch-based classifier ensemble. Neuroradiology (2014) 0.77
Longitudinal relaxographic imaging of white matter hyperintensities in the elderly. Fluids Barriers CNS (2014) 0.77
Genome wide analysis of novel copy number variations duplications/deletions of different epileptic patients in Saudi Arabia. BMC Genomics (2015) 0.77
Neurological imaging: statistics behind the pictures. Imaging Med (2011) 0.76
Morphometric abnormalities of the lateral ventricles in methamphetamine-dependent subjects. Drug Alcohol Depend (2013) 0.76
An efficient approach for differentiating Alzheimer's disease from normal elderly based on multicenter MRI using gray-level invariant features. PLoS One (2014) 0.76
Age-related differences in the structural complexity of subcortical and ventricular structures. Neurobiol Aging (2016) 0.76
Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Dis Assoc Disord (2013) 0.76
Surgery is associated with ventricular enlargement as well as cognitive and functional decline. Alzheimers Dement (2015) 0.76
Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer's Disease. Aging Dis (2017) 0.75
Spatio-Temporal Regularization for Longitudinal Registration to Subject-Specific 3d Template. PLoS One (2015) 0.75
Shape-Attributes of Brain Structures as Biomarkers for Alzheimer's Disease. J Alzheimers Dis (2016) 0.75
Calculating stage duration statistics in multistage diseases. PLoS One (2011) 0.75
Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. J Alzheimers Dis (2016) 0.75
Making use of longitudinal information in pattern recognition. Hum Brain Mapp (2016) 0.75
Joint Data Harmonization and Group Cardinality Constrained Classification. Med Image Comput Comput Assist Interv (2016) 0.75
"Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res (1975) 301.74
A new rating scale for Alzheimer's disease. Am J Psychiatry (1984) 15.16
The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging (2008) 14.68
Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (2005) 12.04
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
Sample size and optimal designs for reliability studies. Stat Med (1998) 6.80
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage (2004) 5.07
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol (2000) 3.99
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol (2001) 3.54
Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology (2003) 2.85
Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging (1998) 2.75
Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging. Neuroimage (2003) 2.52
Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer's disease. Ann Neurol (1998) 1.86
Hippocampal, amygdalar, and global brain atrophy in different apolipoprotein E genotypes. Neurology (2002) 1.82
Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology (2008) 1.80
Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Neurology (2005) 1.73
Volumetric MRI and cognitive measures in Alzheimer disease : comparison of markers of progression. J Neurol (2008) 1.60
Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging (1994) 1.42
Ventricular volume and dementia progression in the Cardiovascular Health Study. Neurobiol Aging (2006) 1.36
Shape differences of the brain ventricles in Alzheimer's disease. Neuroimage (2006) 1.35
Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord (2007) 1.20
Volumetric correlates of memory and executive function in normal elderly, mild cognitive impairment and Alzheimer's disease. Neurosci Lett (2006) 1.15
Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Br J Radiol (2002) 1.09
MR image-based measurement of rates of change in volumes of brain structures. Part II: application to a study of Alzheimer's disease and normal aging. Magn Reson Imaging (2002) 1.05
Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord (2005) 1.04
Dementia, quantitative neuroimaging, and apolipoprotein E genotype. AJNR Am J Neuroradiol (2001) 1.03
Reliability of estimates of changes in mental status test performance in senile dementia of the Alzheimer type. J Clin Epidemiol (1990) 0.96
Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers. Pharmacogenomics J (2004) 0.92
Temporal horn index and volume of medial temporal lobe atrophy using a new semiautomated method for rapid and precise assessment. AJNR Am J Neuroradiol (2006) 0.89
Inheritance of the ApoE epsilon4 allele increases the rate of brain atrophy in dementia patients. Dement Geriatr Cogn Disord (1999) 0.87
Relationship between the efficacy of rivastigmine and apolipoprotein E (epsilon4) in patients with mild to moderately severe Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 0.85
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiol Drug Saf (2007) 0.82
[Volumetric MRI for evaluation of regional pattern and progressin of neocortical degeneration in Alzheimer's disease]. Radiologe (2003) 0.81
Influence of cognitive reserve on neuropsychologic functioning in Alzheimer's disease type sporadic in subjects of Spanish nationality. Neuropsychiatry Neuropsychol Behav Neurol (2002) 0.80
Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Dement Geriatr Cogn Disord (2004) 0.79
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet (2011) 11.28
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage (2011) 5.24
Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain (2009) 4.51
Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain (2010) 4.39
Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database. Neuroimage (2010) 4.28
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage (2007) 4.07
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage (2011) 3.47
Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects. Neuroimage (2008) 3.40
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage (2010) 3.27
Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage (2009) 3.13
Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement (2010) 3.11
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst (2005) 3.08
Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol (2012) 3.03
Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. Radiology (2009) 2.90
Optic disc edema, globe flattening, choroidal folds, and hyperopic shifts observed in astronauts after long-duration space flight. Ophthalmology (2011) 2.88
Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement (2010) 2.88
Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One (2009) 2.85
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol (2011) 2.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement (2010) 2.79
Voxelwise genome-wide association study (vGWAS). Neuroimage (2010) 2.69
Different data from different labs: lessons from studies of gene-environment interaction. J Neurobiol (2003) 2.68
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease. Brain (2009) 2.61
Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer (2007) 2.55
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain (2009) 2.51
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
Bias in tensor based morphometry Stat-ROI measures may result in unrealistic power estimates. Neuroimage (2011) 2.50
Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset. Neuroimage (2009) 2.47
Automatic quality assessment in structural brain magnetic resonance imaging. Magn Reson Med (2009) 2.43
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol (2011) 2.41
3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. Neuroimage (2008) 2.40
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. Neuroimage (2010) 2.32
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement (2013) 2.32
Multi-modal imaging predicts memory performance in normal aging and cognitive decline. Neurobiol Aging (2008) 2.31
Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.30
Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects. Neuroimage (2009) 2.28
Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Hum Brain Mapp (2009) 2.28
Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage (2010) 2.27
Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage (2008) 2.25
Structural MRI biomarkers for preclinical and mild Alzheimer's disease. Hum Brain Mapp (2009) 2.24
Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data. Neuroimage (2009) 2.22
Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry (2002) 2.20
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. Neurology (2009) 2.18
CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease. J Neurosci (2010) 2.18
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Boosting power for clinical trials using classifiers based on multiple biomarkers. Neurobiol Aging (2010) 2.13
A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A (2010) 2.12
Statistical analysis of longitudinal neuroimage data with Linear Mixed Effects models. Neuroimage (2012) 2.11
LEAP: learning embeddings for atlas propagation. Neuroimage (2009) 2.09
The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes. Alzheimers Dement (2010) 2.09
MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology (2011) 2.08
Fertility and sexual function in long-term survivors of haematological malignancy: using patient-reported outcome measures to assess a neglected area of need in the late effects clinic. Br J Haematol (2013) 2.06
Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage (2009) 2.03
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology (2014) 2.03
Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. Neuroimage (2009) 1.95
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease. Neuroimage (2010) 1.94
Genome-wide association study of Alzheimer's disease. Transl Psychiatry (2012) 1.88
Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters. Neuroimage (2010) 1.87
Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology (2010) 1.86
Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents. Magn Reson Med (2008) 1.85
Ensemble sparse classification of Alzheimer's disease. Neuroimage (2012) 1.84
Elimination of the vesicular acetylcholine transporter in the striatum reveals regulation of behaviour by cholinergic-glutamatergic co-transmission. PLoS Biol (2011) 1.84
Nonlinear registration of longitudinal images and measurement of change in regions of interest. Med Image Anal (2011) 1.82
The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol (2011) 1.79
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One (2011) 1.79
Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials. Neuroimage (2012) 1.76
Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol (2011) 1.75
Abnormal cortical networks in mild cognitive impairment and Alzheimer's disease. PLoS Comput Biol (2010) 1.72
BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage (2011) 1.72
Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease. Neuroimage (2009) 1.71
Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage (2009) 1.71
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Neuroimage (2010) 1.69